The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | LOCOMMOTION: analysis of SOC for R/R myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the LOCOMMOTION trial (NCT04035226) – the first prospective study of the efficacy and safety of real-life standard of care (SOC) regimens in patients with relapsed/refractory (R/R) multiple myeloma – and shares an update on interim analysis findings. Interim results demonstrated that heavily pretreated, triple-class exposed patients with R/R multiple myeloma continue to progress after multiple lines of therapy and have poor outcomes. Dr Mateos highlights the lack of SOC for triple-class refractory patients and concludes that new treatments with novel mechanisms of action are needed. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Honoraria from lectures and participation in boards from: Janssen, BMS-Celgene, Abbvie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio, Sea-Gen.
